Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancy: Initial Report from Shiraz Surgical Oncology Group
نویسندگان
1 Breast Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
2 Breast Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
3 Maternal-Fetal Medicine Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
4 Breast Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
5 Breast Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
6 Breast Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
7 Breast Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
8 Gynecology Oncology Division, Department of Obstetrics and Gynecology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
doi
10.30476/mejc.2021.87830.1440چکیده
Background: Hyperthermic intraperitoneal chemotherapy (HIPEC) is increasingly used to treat peritoneal carcinomatosis (PC). The objective was to evaluate the outcomes of cytoreductive surgery (CRS) and HIPEC in our center.Method: In this retrospective study, data were collected from 43 patients with PC who underwent CRS-HIPEC in 2016 at Faghihi Hospital of Shiraz University of Medical Sciences. Outcomes were collected and analyzed. Analyses were conducted through SPSS 23. P-value < 0.05 was considered to be statistically significant.Results: The mean age of the patients was 52.23 پ} 11.82 years. The participants in the study analysis consisted of 36 female (83.7%) and seven male patients (16.3%). The most common primary tumor was ovarian cancer (62.8%). Completeness of the cytoreduction score of CC0/CC1 was obtained in 87.7% of the patients. The 1- and 3- year overall survivals were 88% and 60%, respectively.Conclusion: Our study supports that employing CRS and HIPEC for PC is feasible with acceptable morbidity in our center.
